{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-024920","form_type":"8-K","ticker":null,"cik":"0001827506","company_name":"Tourmaline Bio, Inc.","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.932734+00:00","generated_at":"2026-06-14T11:53:37.688315+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Talaris CEO departs; CFO Fenton takes interim CEO role; strategic review underway","bullets":["Scott Requadt left as CEO and President effective May 26, 2023; no disagreement cited.","CFO Mary Kay Fenton appointed interim CEO and President, remaining CFO.","Requadt to receive $50,000/month as strategic advisor through August 26, 2023.","Company conducting strategic review including possible business combination or divestiture.","Workforce reduction previously announced; no timetable set for review."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-024920","json":"https://secwatch.observer/filing/0000950170-23-024920.json","markdown":"https://secwatch.observer/filing/0000950170-23-024920.md","text":"https://secwatch.observer/filing/0000950170-23-024920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/0000950170-23-024920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/tals-20230526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T11:53:37.688315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ba85522d0","claim":"Mary Kay Fenton was appointed as Interim Chief Executive Officer and President at Tourmaline Bio, Inc..","evidence_excerpt":"Effective May 26, 2023, the Board of Directors of the Company (the “ Board ”) appointed Mary Kay Fenton, the Company’s Chief Financial Officer, as Interim Chief Executive Officer and President, until a successor is appointed.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/0000950170-23-024920-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"2f536d5f04","claim":"Scott Requadt departed as Chief Executive Officer and President at Tourmaline Bio, Inc..","evidence_excerpt":"As previously announced, effective May 26, 2023, Scott Requadt left his role as Chief Executive Officer and President of Talaris Therapeutics, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/0000950170-23-024920-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"left"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"b1174c5726","claim":"Scott Requadt resigned as Director at Tourmaline Bio, Inc..","evidence_excerpt":"Mr. Requadt notified the Company of his intent to resign from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/0000950170-23-024920-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}